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New  interventions  are  needed  to reduce  morbidity  and mortality  associated  with  malaria,  as  well as  to
accelerate  elimination  and  eventual  eradication.  Interventions  that  can break  the  cycle  of parasite  trans-
mission, and  prevent  its reintroduction,  will be  of  particular  importance  in achieving  the eradication  goal.
In this regard,  vaccines  that interrupt  malaria  transmission  (VIMT)  have  been  highlighted  as  an  important
intervention,  including  transmission-blocking  vaccines  that  prevent  human-to-mosquito  transmission
by  targeting  the  sexual,  sporogonic,  or mosquito  stages  of  the  parasite  (SSM-VIMT).  While  the  signiﬁ-alaria vaccine
ransmission blocking
limination
radication
cant  potential  of this  vaccine  approach  has  been  appreciated  for decades,  the development  and  licensure
pathways  for  vaccines  that  target  transmission  and  the  incidence  of infection,  as  opposed  to  prevention
of  clinical  malaria  disease,  remain  ill-deﬁned.  This  article  describes  the  progress  made  in  critical  areas
since 2010,  highlights  key  challenges  that remain,  and  outlines  important  next  steps  to  maximize  the
potential  for SSM-VIMTs  to contribute  to  the  broader  malaria  elimination  and  eradication  objectives.
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1. Introduction
The 2013 update to the Malaria Vaccine Technology Roadmap
(Roadmap) expanded the vision to develop “safe and effective vac-
cines against Plasmodium (P.) falciparum and P. vivax that prevent
disease and death and prevent transmission to enable malaria erad-
ication” and introduced an important new strategic goal: “The
development of malaria vaccines that reduce transmission of the
parasite and thereby substantially reduce the incidence of human
malaria (parasite) infection” [1]. This complemented the original
2006 Roadmap strategic goal of developing a highly efﬁcacious vac-
cine to prevent clinical disease [2] and highlighted the deﬁnitive
shift of the broader malaria community to a focus on the develop-
ment of tools to accelerate elimination and eventual eradication
of malaria. The leadership of the Bill & Melinda Gates Founda-
tion (Gates Foundation), along with the World Health Organization
(WHO), the Roll Back Malaria Partnership, and other key stakehold-
ers, have challenged the malaria community to renew its efforts to
eradicate malaria [3], therefore leading to a signiﬁcant refocusing
of associated product development efforts [4].
Over the last several years, as the malaria community began to
embrace the challenge of eradication, questions arose about the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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easibility of such an endeavor, the tools and strategies that would
nable it, and the gaps that would need to be addressed in order to
upport eradication as a long-term goal. A number of meetings and
onsultations took place in and around 2010 to deﬁne the research
genda for malaria eradication, including those associated with the
evelopment of a malaria vaccine to interrupt malaria (parasite)
ransmission (VIMT) [5–16]. Initially P. falciparum and P. vivax were
rioritized, with the recognition that to truly eradicate malaria, all
pecies that infect humans must eventually be addressed. This arti-
le describes the progress that has since been made in critical focus
reas identiﬁed during those meetings (Clinical development path-
ay and regulatory strategy; Assays; Transmission measures and
pidemiology; Communications and ethics; Policy and access; Pro-
ess development and manufacture; speciﬁc challenges associated
ith targeting P. vivax), and highlights the next steps that will be
ritical to developing the classes of vaccines needed to support the
ommunity’s malaria-eradication goals, as laid out in the revised
oadmap.
While vaccines have the potential to interrupt malaria trans-
ission at multiple points in the parasite lifecycle, this paper will
ocus on strategies targeting the sexual, sporogonic, and mosquito
SSM) stages of the parasite (hereafter referred to as an SSM-VIMT),
hich are involved in the transmission of malaria parasites from an
nfected person to a female mosquito, rather than those involved
n parasite infection of the human host or causing malaria disease.
hile not a novel concept, as evidenced by the 2000 meeting report
n transmission-blocking vaccines (TBVs), “an ideal public good”
17], the product development resources now available to apply
o the development of such products have created signiﬁcant new
pportunities. Unique development challenges associated with this
lass of VIMT, most notably the delayed as opposed to immediate
eneﬁt conferred to immunized individuals, require special con-
ideration.
. Ideal characteristics of an SSM-VIMT
The availability of a target product proﬁle (TPP), in which key
referred and minimally acceptable characteristics of the vaccine
ave been deﬁned, at an early stage in development helps ensure
lignment between the product developed and the developing-
ountry context in which its use is intended [18,19]. The PATH
alaria Vaccine Initiative (MVI) presented a draft TPP for a stand-
lone SSM-TBV against both P. falciparum and P. vivax that was used
s the basis for discussion at the MVI-sponsored TBV workshop in
010 and the malaria vaccine advisory committee (MALVAC) meet-
ng the same year [15]. There was consensus among participants
n a number of key elements, including that the vaccine would
eed to be amenable to campaign administration, and therefore
afe for administration to all who may  transmit malaria parasites,
ffective in as few doses as possible for as long as possible, and
ow cost [16]. The WHO  is currently leading an effort to develop
onsensus preferred product characteristics to guide the commu-
ity’s progress toward developing a VIMT that meets the updated
oadmap goals; the characteristics with outstanding questions are
escribed below.
A critical gap in the TPP is the required vaccine effect (a com-
ination of factors including efﬁcacy and coverage) [20] needed
o support elimination efforts. Preliminary modeling data indicate
hat efﬁcacy and coverage are equally important in the impact of
 TBV [21]. Although the implications of this relationship on the
equired level of vaccine efﬁcacy are not yet known, it is of crit-
cal importance to identify the minimally required efﬁcacy (and
overage) to support deﬁning stage-gate criteria that will inform
arly clinical decision-making. In addition to mathematical mod-
ls (reviewed in the Malaria Eradication Research Agenda [malERA]2 (2014) 5531–5539
Consultative Group on Modeling, 2011 [8]), biological and popula-
tion models may  also help to inform these criteria [20].
There is general agreement that a vaccine designed to contribute
to elimination would need to be suitable for use in campaigns;
however, it is still too early to have consensus on its exact formu-
lation. In addition to the development of a stand-alone SSM-VIMT,
which would not confer an immediate, direct beneﬁt to the vac-
cine recipient, a vaccine targeting both SSM and other stage malaria
antigens, a vaccine co-formulated with one targeting a different dis-
ease, and/or co-administration with another health intervention
that targets the same population have been proposed. Strategies
of combining antigens from different stages of the parasite lifecy-
cle (such as RTS,S [22]) or of co-administering the vaccine with
a transmission-blocking drug are some of those currently being
explored and could prove to be synergistic, while leveraging the
successes in product development to date.
There has been signiﬁcant debate on the merits of targeting anti-
gens that are expressed while the parasite resides in the human,
thus creating opportunity for an anamnestic immune response
upon subsequent infection. As elimination is approached, fewer
and fewer infections will occur, perhaps making natural boosting
of a protective immune response a less impactful attribute of a
product’s TPP. Furthermore, expression in the human increases the
possibility that immune selection will lead to the proliferation of
escape mutants. Additional data are therefore needed to support
whether endemic boosting should be a critical attribute of an ideal
SSM-VIMT.
3. Clinical development plan and regulatory pathway
The clinical development plan (CDP) and the basis of regula-
tory approval for an SSM-VIMT will likely be different from those
applied to pre-erythrocytic and blood-stage malaria vaccines due
to the methods in which vaccine effect will be established at the
level of the community rather than the individual. In 2010, the
major points of discussion on CDP/regulatory pathway were on
the acceptability to regulatory authorities of a vaccine acting via
delayed clinical beneﬁt, the appropriate CDP and regulatory path-
way, including the potential need for a cluster randomized trial
(CRT), and the required level of efﬁcacy.
A critical outcome of the 2010 MVI  TBV workshop was that the
US Food and Drug Administration (FDA) indicated that there is no
legal bar to prevent a vaccine such as an SSM-TBV from being con-
sidered for licensure in the context of their review process. The FDA
has the authority to license biological products that are demon-
strated to be “safe, pure, and potent” (Section 351 of the Public
Health Service Act & Section 505(b) of the Food, Drug, and Cosmetic
Act), regardless of whether the disease occurs in the United States
[23]. This feedback has encouraged the malaria vaccine devel-
opment community to consider product development pathways
for vaccine approaches exclusively targeting parasite transmission
from human to mosquito. In 2012, moreover, the report on the
MALVAC meeting states, “great progress has been made in recent
years with a general acceptance in malaria vaccine circles that the
issue of community beneﬁts for TBV is not a major hurdle for clin-
ical or regulatory pathways” [24]. The challenge moving forward
will be to further deﬁne both the CDP and regulatory pathways and
seek speciﬁc feedback from regulators, such as the FDA, European
Medicines Agency, or another stringent regulatory authority.
Another important outcome of the VIMT research agenda-
setting meetings and consultations was the preliminary deﬁnition
of two potential clinical development pathways for an SSM-VIMT
(Fig. 1). One involves a large-scale, Phase 3 efﬁcacy trial, which,
in the case of an SSM-VIMT, has been proposed by regulators to
be a CRT to demonstrate vaccine impact on incidence of infection
J.K. Nunes et al. / Vaccine 32 (2014) 5531–5539 5533
Fig. 1. Diagram of two potential clinical/regulatory pathways for an SSM-VIMT. In one potential pathway (the Phase 3 CRT-based pathway), regulatory approval is based
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ot  clinically, validated surrogate of efﬁcacy, and depends on the success of the wor
s  included in the formulation, a more traditional regulatory strategy could be cons
n the community. An accelerated approval pathway, such as the
ne used by the FDA [25], was also discussed in which the vaccine
ould receive approval for use based on an analytically and biolog-
cally, but not clinically, validated surrogate of efﬁcacy (which does
ot yet exist), with impact on transmission at the community level
onﬁrmed during post-approval studies. In the latter approach, the
uccess of the work described under Assays and Correlates will be
ritical for this regulatory pathway to be considered acceptable.
or the approval pathway based on a single CRT, the feasibility
f conducting such a study, the statistical power to conclusively
emonstrate the efﬁcacy of the vaccine, and the translation of those
esults to the variety of settings contemplated for introduction of
n SSM-VIMT, are important questions that need to be answered.
Toward identiﬁcation of the preferred regulatory strategy, MVI
as convened a series of technical consulting groups composed of
ndependent experts to elucidate both of these potential CDP and
egulatory pathways, considering overall feasibility, speciﬁc end-
oints, requisite baseline data, malaria transmission levels, scale,
nd cost. The reports generated by these technical groups will be
sed to prepare a brieﬁng document for consultation with regu-
atory authorities on the preferred approach, which will impact
ther areas of vaccine development, from ethics to policy to assays
see Table 1). Finalizing a CDP/regulatory pathway will require
oordination with those assessing the measures of transmission
nd epidemiological data needs of SSM-VIMT trials. Alongside the
fforts to ﬁnalize a regulatory pathway and CDP, progress must
ontinue in the strengthening of clinical and regulatory capacity
f endemic countries, where clinical trial sites will be selected in
ccordance with the CDP.
The level of efﬁcacy required for an SSM-VIMT to have an impact
n transmission and contribute to achieving elimination has not yet
een determined. In 2010, the draft TPP presented at the MVI  TBV
orkshop targeted ≥85% transmission-blocking efﬁcacy, deﬁned
s the percent reduction in infection in mosquitoes [26]. However,
here were not yet robust data to support a speciﬁc target efﬁcacy.
urthermore, as the ultimate goal is to prevent incidence in the
uman population, a measure of efﬁcacy that reﬂects vaccine effect
n a human endpoint must be utilized. Initial evidence was  recently
eported using a population-based, non-clinical model of malariad pathway for regulatory approval is based on an analytically and biologically, but
ribed under Assays and Correlates. If a component providing direct, clinical beneﬁt
.
transmission indicating that interventions with lower efﬁcacy lev-
els may  contribute to elimination [20]. Just as targeting antigens
from multiple parasite stages may  create synergies, the use of a
vaccine and drug together could maximize the impact on trans-
mission. For example, a drug could be used to clear the parasites
from an infected individual at the same time as administration of a
SSM-VIMT, which would prevent transmission for a longer period
than a drug could. Coordination of development strategies between
the drug and vaccine communities through the alignment of TPPs
will ensure the most efﬁcient progress toward common goals.
4. Assays and Correlates
To determine whether an SSM-VIMT candidate is able to block
transmission, reliable assays are required that measure the ability
of an immunized, infected individual’s serum to prevent sporo-
gony in and subsequent invasion of the mosquito mid-gut after a
blood meal, as the traditional endpoints used to evaluate efﬁcacy
against future episodes of clinical disease are not informative (see
Box 1). The decision to pursue a CDP in which licensure is based
on a single CRT or to pursue a CDP relying on analytical endpoints
(described above) to secure accelerated approval will signiﬁcantly
impact the level of development needed for such functional assays.
As of 2010, the two major areas of focus for feeding assays were
their reproducibility (in relation to their ability to be qualiﬁed), and
the correlation between lab and ﬁeld assays (outcomes of the 2010
MALVAC meeting and malERA consultations have been detailed
elsewhere in the literature [13,15,16]).
The prospect of qualifying the standard membrane feeding assay
(SMFA) had been questioned due to a lack of reproducibility. The
SMFA had demonstrated a low sensitivity in addition to the ques-
tions about its utility in the middle ranges of transmission-blocking
activity [15]. Since 2010, signiﬁcant progress has been made and
the SMFA assay has been qualiﬁed for the characteristics of preci-
sion, linearity, range, and speciﬁcity. The range of the assay was
limited to results of 80% or greater reduction in oocyst density,
though modiﬁcations could potentially expand this range [27].
Future efforts continue toward full qualiﬁcation of the assay, which,
along with conclusive evidence that it predicts outcomes from more
5534 J.K. Nunes et al. / Vaccine 32 (2014) 5531–5539
Table 1
Impact of choice of clinical regulatory pathway on SSM-VIMT development.
Approval based on
CRT
Accelerated
approval
Ideal
characteristics
No impact. No impact.
Process
development and
manufacture
No impact. No impact.
Assays and
Correlates
Assays required to
move development
forward, but
surrogate not
required.
Surrogate
approved by
regulatory
authority required.
Transmission
measures and
epidemiology
Speciﬁc baseline
data would be
required to
appropriately and
accurately design
the CRT.
Speciﬁc baseline
data may  be
required to
measure the
surrogate.
Communication
and  ethics
Ethical issues
associated with
CRTs would need to
be addressed (e.g.,
randomization of
communities to
receive
intervention).
Sites for clinical
trials may  not be
the same as those
targeted for ﬁrst
deployment,
presenting ethical
challenges.
Communication of
results would
require distinct
messaging.
Use of a
conditionally
approved vaccine
in trials would
require speciﬁc
messaging, and
necessitate close
ethical
consideration.
Policy and access Analysis required
to determine which
pathway would
allow vaccine use
sooner in areas
where most impact
will be made.
Design of
post-approval
efﬁcacy studies
would be more
informed by
modeling, which
would also require
regulatory support.
Clinical trial site
selection
Sites capable of
conducting CRT
would be needed in
areas with very
speciﬁc
transmission
levels: sufﬁcient to
limit sample size
and make
conclusive results
likely, yet low
enough to measure
vaccine effect.
Data generated at
clinical trial sites in
areas that still have
moderate
transmission
would be used for
regulatory
approval. These
may  not be the ﬁrst
regions to
implement an
SSM-VIMT, and the
ethical
implications would
b
[
a
d
i
e
n
u
f
e
w
e
Box 1: Membrane feeding assays.
Definitions
Standard membrane feeding assay (SMFA): Laboratory-based
assay where lab-reared mosquitoes feed on cultured P. falci-
parum gametocytes through a membrane, as depicted below.
Direct membrane feeding assay (DMFA): Field-based assays
(carried out in endemic areas) where progeny of wild-caught
mosquitoes feed on a blood meal from a malaria-infected host
through a membrane.
Direct feeding assay (DFA): Field-based assays (carried out
in endemic areas) where progeny of wild-caught mosquitoes
feed directly through the skin of a malaria-infected host.
Assay readouts
For a week following a feed, all mosquitoes are kept alive to
allow ingested parasites to develop into oocysts. Mosquitoes
are then dissected and the number of oocysts counted in
the mid-guts. (MVI is supporting efforts to develop higher
throughput, less labor-intensive methods for determining the
number of oocysts in the mosquito mid-gut.) For the SMFA,
the results are reported as a percent reduction in the number
of oocysts compared to a pre-immune control. The SMFA  read-
out, reduction in oocyst intensity, can be understood as oocyst
reducing/inhibiting activity. For the ﬁeld assays, results can be
reported in a binary fashion, where mosquitoes are scored as
having oocysts or not (oocyst prevalence). This readout can
be referred to as transmission-blocking activity, and indicates
whether or not the mosquito was infected and had the poten-
tial to transmit disease. In the context of a malaria program
reaching elimination, this is the most relevant readout.
Bridging lab- and field-based assays
How the lab- and ﬁeld-based assays relate to one another, and
how a vaccine candidate that performs well (strong oocyst
reducing activity) in the SMFA  will perform in a ﬁeld-based
feeding assay (DMFA or DFA), is not well understood. Fol-
lowing the review described under “Assays and Correlates,”
MVI-funded efforts on bridging the assays are underway with
the hope to have clearer understanding of the relationship
between the lab and ﬁeld assays in the coming year or two.
How robust the feeding assays need to be will depend on the
clinical development path chosen (see Fig. 1), as an assay that
can serve as a surrogate for transmission reduction in humansneed to be
addressed.
iologically relevant assays (e.g., direct membrane feeding assay
DMFA] and direct feeding assay [DFA]), will inform the role of the
ssay in the development of an SSM-VIMT.
In 2012, MVI  facilitated an experiment to assess the repro-
ucibility of the SMFA across laboratories in response to the
dentiﬁed gaps. Using a blinded, standardized antibody panel
ncompassing a range of predetermined inhibitory activities, a
umber of laboratories performed independent runs of the SMFA
sing their own standard operating procedures, and the raw data
rom each were analyzed by one group. Preliminary results were
ncouraging, and further work is now being pursued to determine
hether the comparison of vaccine candidates being developed and
valuated by independent groups will be possible.will be required for the shorter path to licensure.
To address the identiﬁed knowledge gap with respect to the
correlation between the SMFA and transmission reduction in the
ﬁeld, MVI  coordinated a review to compare results from the DMFA
and DFA [28] in terms of efﬁciency of parasite infection and to bet-
ter understand variability within the DMFA. In summary, the group
found that the DFA is a more efﬁcient means of infecting mosquitoes
than the DMFA, though the mosquito infection rates in the DFA
strongly correlated with those in the DMFA. Their work also high-
lighted some differences in the feeding assay methodology, which
might have contributed to assay variability and identiﬁed some
gaps in our knowledge of the performance of the assays. As our
understanding of the utility of each feeding assay in the different
stages of vaccine development matures, the interpretation of assay
readouts is also evolving (see Box 1).
To progress toward the Roadmap strategic goal of a vaccine
that reduces transmission, MVI  released a Call for Proposals to
improve the existing assays and to address the gaps in the knowl-
edge of how the assays relate to each other. The following priority
areas were targeted: quantiﬁcation of variability in feeding assays;
cine 3
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ssay improvements or surrogates; and factors intrinsic to the par-
site, mosquito vector, or human host that inﬂuence transmission.
rojects currently supported by MVI  include those that address
ptimizing the SMFA, correlating results of SMFA to DMFA, opti-
izing the DMFA and DFA, alternative methodology and readouts
or the assays, reagent development, and developing a lab-based
odel to evaluate transmission dynamics.
. Transmission measures and epidemiology
Transmission measures and epidemiology (TM&E) is a broad
rea in which large gaps in data had been identiﬁed, from a basic
nderstanding of the parasite reservoir and the dynamics of trans-
ission to the development of new, and further characterization
f existing, methods to measure transmission. These issues are
ommon across all efforts to eliminate malaria and not speciﬁc to
accine development. Therefore, the ﬁeld of TM&E may  stand to
ain the most from increased collaboration and data sharing. Spe-
iﬁc to vaccine development, the projects described below will help
o inform TPP development, clinical trial site selection, and clinical
rial endpoint identiﬁcation, as well as provide information on the
ppropriate use and evaluation of the impact of an SSM-VIMT in
ifferent transmission settings and in combination with different
nterventions. All of the work in these areas could not be covered
n this article, which highlights projects supported by MVI  [29] and
he Malaria Eradication Scientiﬁc Alliance (MESA) [30], the Gates
oundation-funded continuation of the malERA project.
To address the need for a comprehensive assessment of current
. falciparum transmission measures, MVI  sponsored an evaluation,
hich would also evaluate the correlations between measures5
nd their appropriateness for use in the ﬁeld. Conducted at the
ondon School of Hygiene and Tropical Medicine and the Johns
opkins University, the evaluation included: (1) describing their
ethodology, precision, accuracy, and cost; (2) evaluating which
easures work best in each setting; (3) deﬁning the mathemat-
cal relationship between measures; and (4) recommending the
ost appropriate measures for monitoring changes in transmis-
ion to evaluate malaria interventions. The results were described
n Tusting et al. [31]. With respect to the mathematical relation-
hip between some of the entomological measures, it was found
hat insufﬁcient data were available and a collaborative project was
egun [32],6 which relies on the generous sharing of data between
esearchers. A MESA-sponsored investigation will compare the per-
ormance of a number of current epidemiological, molecular, and
erological transmission measures in a variety of settings, including
ery low transmission, for both P. falciparum and P. vivax [33].
The development of novel methods for measuring infection, dis-
ase, and transmission, in particular identifying people carrying
nfectious gametocytes, including asymptomatic individuals, for
oth P. vivax and P. falciparum infection could be important tools for
he broader effort to eliminate malaria, as well as the development
f VIMTs. Such methods would need to be not only standardized,
apid, sensitive, and capable of high throughput, but should also be
ow cost and appropriate for use in low-transmission settings [10].
5 The analysis included the following measures of transmission: net infectious-
ess of humans (the proportion of mosquitoes that become infected after feeding
n  humans), parasite prevalence in humans, entomological inoculation rate, force of
nfection and molecular force of infection, multiplicity of infection, seroconversion
ate, slide or clinical positivity rate, incidence of clinical malaria or annual parasite
ndex, proportion of fevers with P. falciparum parasitaemia, vectorial capacity, and
asic reproduction number.
6 Conjugation to Pseudomona aeruginosa exoprotein A (EPA), diphtheria toxin
CRM197), E. coli outer membrane protein C precursor (OMPC), and tetanus toxoid
TT)  are being considered.2 (2014) 5531–5539 5535
To target speciﬁc populations and gametocyte carriers, the abil-
ity to quickly generate higher-resolution maps that show human
risk and disease in a spatial and temporal manner, track migrant
populations, link with surveillance systems, and contain more
detail on ecological factors, mosquito breeding sites, and quanti-
ﬁed vector capacity will be critical to the entire ﬁeld of malaria
elimination [10]. A MESA-supported project will map  transmission
potential in countries targeting elimination and determine whether
new cases have been imported using parasite genetics [33]. Data
sharing between those researching transmission measures and
those collecting ecological and epidemiological data would further
facilitate progress.
Ongoing basic research to support the gaps identiﬁed above
include the relationship between infectivity of humans to
mosquitoes (including the role of asymptomatic individuals), the
infectious reservoir [32,34] and transmission [35,36], the extent
and importance of naturally acquired transmission-blocking activ-
ity [37], and the nature and importance of changes in parasite
genetic diversity that might occur as transmission declines [38].
6. Communications and ethics
Effective public health communications and consideration of
ethical concerns are critical for the design, development, and use of
any vaccine, but are particularly important for an SSM-VIMT given
that beneﬁt is experienced as a community, with delayed individual
beneﬁt. The priority needs for communications related to TBVs that
had been highlighted at the MVI  TBV workshop, MALVAC meeting,
and in the malERA publications, were a re-framing of the beneﬁts of
TBVs to individuals and communities, research on the best way  to
engage communities, the development of strategies to ensure the
continued use of other malaria control interventions, and establish-
ment of the acceptability of a vaccine that would provide protection
at the community level.
The concept of a vaccine that does not provide immediate,
direct clinical protection to the recipient, while novel to the ﬁeld of
malaria, is not unprecedented in vaccinology; accordingly, ethicists
made a strong recommendation to refrain from referring to SSM-
VIMTs as vaccines that do not provide individual beneﬁt. Rather,
the message that individual beneﬁt will be derived from commu-
nity beneﬁt over time should be communicated [16]. There is now
greater awareness of the other examples of vaccines and drugs that
aim to limit disease in one population by treating another (although
in the case of an SSM-VIMT, given the local and focal nature of
malaria transmission, many of the recipients would likely also be
the beneﬁciaries). In addition to the examples of vaccines given to
one population to protect another, such as those against rubella [39]
and cytomegalovirus [40,41], primaquine is administered in some
countries to P. falciparum-infected patients [42] to kill the sexual
stage parasites and prevent disease transmission, despite the fact
that it does not alleviate their symptoms [43,44]. Countries may
require a particular vaccine, such as yellow fever, to prevent disease
importation [45], and an SSM-VIMT against malaria could be used
similarly to prevent reintroduction of the parasite into malaria-free
zones.
MVI  has conducted a series of community perception studies
on malaria and pre-erythrocytic vaccines that address the call for
research on community engagement and maintaining the use of
other interventions following introduction of any malaria vaccine
[46–48]. Attitudes were positive toward vaccines overall, and there
was concern about malaria and its impact on a family’s economic
stability. People were aware of the importance of and need for
malaria interventions. An important consideration highlighted by
the studies, and that will also be applicable to an SSM-VIMT, was
the need to obtain the endorsement of local community leaders
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and the low endemicity in many countries (which prevents the
development of immunity) [64,65]. The updated Roadmap goals
call for vaccines against P. vivax [1], yet the overall strategy,536 J.K. Nunes et al. / Vac
nd to ensure their involvement in the developing and spreading
f communication messages [46–48].
More work will need to be done to assess communities’ under-
tanding and acceptance of a vaccine that provides delayed beneﬁt
t the level of the community, but these initial studies suggested
hat the proposed ideal target population for an SSM-VIMT is
ligned with the communities’ needs; indeed, people expressed
oncern that the most advanced malaria vaccine candidates are
urrently targeted only to infants and young children [46–48]. To
chieve elimination, it would be ideal to deﬁne the target popula-
ion as all those who are likely to transmit malaria. Such a target
ay  include groups that are not accustomed to receiving vaccines,
uch as children above three years of age, women of childbearing
ge, and adult men. MVI  plans to conduct a customer survey that
ill address this and other questions of SSM-VIMT acceptability
t the community level. A working group of experts has also been
onvened, which could serve as a forum to coordinate the overall
ommunications and ethics efforts in the malaria community.
. Policy and access
Adequate consideration of policy and access issues will be criti-
al to ensure that a vaccine most appropriate for the community’s
oals is developed, and that it becomes available and accessible to
he intended audience. Two of the three main points of discussion
egarding policy and access have been covered above: whether a
accine that did not provide immediate, direct clinical protection
ould be accepted by communities (see Section 6), and how to
eﬁne the preferred characteristics of the product (see Section 2).
ther important topics with respect to enabling access to a vaccine
re the delivery strategy (including its health economic impact) and
odeling.
In 2010, the discussion of modeling focused on its potential con-
ribution to developing an SSM-VIMT, and an elucidation of the data
eeded to improve models [15]. Models can play a role in under-
tanding the potential effect of new malaria vaccines, particularly
n the context of other malaria interventions simultaneously in use
nd when ﬁeld data may  be difﬁcult to obtain. Modeling groups
ave committed to articulating the main drivers of their models, as
ell as the limitations of the models and the available data used
o parameterize them [24,49,50]. WHO, MVI, and the Gates Foun-
ation have each encouraged and facilitated data sharing between
odeling groups, with the intention of helping the broader com-
unity understand the models, their outputs, and the signiﬁcance
f any differences between them [51]. In the context of an SSM-
IMT, it is anticipated that modeling results will help deﬁne the
arget efﬁcacy early in the development process, as well as provide
nsight into the potential public health impact of a vaccine in dif-
erent transmission settings. Once the vaccine is approved for use
cross entire communities, introduction studies will be required,
nd they will facilitate validation and reﬁnement of the models.
lthough the current models only apply to P. falciparum,  research
s underway to support the development of models speciﬁc to P.
ivax.
A vaccine that delivers beneﬁt at the community level and is
dministered in campaigns as part of an elimination effort would
equire very large numbers of doses (unless technological advances
llow for rapid, reliable, and inexpensive means of identiﬁcation
f ideal recipients, thereby reducing the necessary volume) and
ay  also require an innovative delivery and access strategy [24],
ith particular attention paid to the economic considerations ofmplementation. A growing body of work (based on modeling) has
xplored the cost-effectiveness of a pre-erythrocytic malaria vac-
ine [49,52] and, while economic evaluation of an SSM-VIMT may
equire distinct analyses, the lessons learned thus far have laid the2 (2014) 5531–5539
groundwork for the research that will need to be conducted into
the economic impact of implementation. A vaccine candidate that
does not provide direct clinical protection to the recipient (as a vac-
cine for travelers or the military must), and does not have a large
market in high-income settings, will not be considered a valuable
addition to the portfolios of Western pharmaceutical companies.
Therefore, cost-reducing strategies should be given high priority,
and it is critical to begin consideration early in development of a
model in which partners are engaged that can contribute to the
signiﬁcant ﬁnancial requirements of product development. In the
context of novel development partnerships that deliver vaccines at
extremely low cost, a major milestone was achieved for meningi-
tis with the approval and introduction of MenAfriVac®, a vaccine
developed in a partnership between PATH, a developing world vac-
cine manufacturer, and WHO  costing less than USD $0.50 per dose
[53]; such a development partnership between a product develop-
ment partnership and WHO  has been identiﬁed as one potential
model for an SSM-VIMT. It was  recently reported that this vac-
cine can be removed from constant refrigeration for mass campaign
administration, which is the ﬁrst such example in Africa and could
extend vaccination coverage to the most remote regions of sub-
Saharan Africa; such an attribute would be ideal for a vaccine for
malaria elimination [54].
8. Process development and manufacture
The implications of campaign delivery for product design are
that the vaccine must have an appropriate risk/beneﬁt ratio, ide-
ally be a single product (versus heterologous prime boost) that
would induce sufﬁcient and lasting antibody titers in as few doses
as possible, exhibit a product proﬁle that is “ﬁt-for-purpose” to sup-
port mass administration, and be cost-effective [15,16]. To identify
SSM-VIMT candidates most likely to meet the preferred charac-
teristics, the community must focus on developing high-quality
immunogens with structure that effectively mimics the native (tar-
get) antigen, toward minimizing the need for potent adjuvants. A
variety of expression systems (Escherichia coli, including cell-free
systems, Lactococcus lactis, Drosophila S2 cells, or Baculovirus insect
cells, plant-based systems [55], and algae [56]) are being explored
for their capacity to produce correctly folded proteins. Through
industry/academic collaborations, all of the leading SSM-VIMT tar-
get antigens (Pfs25, Pfs48/45, Pfs230, AnAPN1) are being considered
for conjugation [57,58],7 in an attempt to enhance their immuno-
genicity, with particular focus on carriers with robust safety data
from use in other vaccines. Another avenue that researchers are
pursuing is evaluation of particle-delivery technologies, such as
virus-like particles [55] (one Pfs25 candidate has entered Phase 1
clinical trials [59]) and nanoparticles [60]. In assessing the merits of
different vaccine strategies, direct comparison of them in relevant
preclinical models will be critical to ensure forward momentum
is maintained with regard to continuous improvement of clinical-
stage candidates.
9. P. vivax
It has become increasingly apparent that P. vivax transmission
will need to be tackled alongside P. falciparum given the recently
recognized disease severity [61–63], the large population at risk,7 Conjugation to P. aeruginosa exoprotein A (EPA), diphtheria toxin (CRM197),
E.  coli outer membrane protein C precursor (OMPC), and tetanus toxoid (TT) are
being considered.
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ncluding development of a TPP, lags behind that for P. falciparum
accines. P. vivax projects also face additional hurdles. Prevent-
ng the transmission of P. vivax is made more complicated by the
resence of the hypnozoite stage of the parasite, which remains
ormant in the liver and often causes relapse disease over the
ourse of the two years following initial infection [66,67], a con-
ideration that must be accounted for when setting the target for
accine duration in the TPP. The lack of standardized reagents for P.
ivax and the inability to routinely conduct a SMFA add to the chal-
enges in developing a TBV against this species [4]. Progress is being
ade in the use of non-human primate models, and increasing
he availability of the P. vivax controlled human malaria infection
CHMI) model would further accelerate vaccine development. With
espect to the latter, the early emergence of gametocytes in P. vivax
nfection (reviewed in [68]), make possible a transmission-blocking
odel for clinically evaluating SSM-VIMTs in early clinical devel-
pment.
0. Conclusion
New tools are needed to accelerate elimination efforts and sup-
ort eventual malaria eradication [5–9,13,14]. A survey of dozens
f previous control/elimination efforts revealed that a rapid resur-
ence of parasite transmission was associated with an inability to
ustain control programs [69]. Therefore, based on our experiences
f the past 70 years, an intervention that could prevent transmis-
ion of malaria parasites between humans and mosquitoes, over
 sustained period of time and with minimal human intervention,
nd therefore maintain effectiveness in the most difﬁcult of envi-
onments, would be a valuable asset in achieving and sustaining
limination. Vaccines that induce immune responses to interrupt
ransmission have the potential to ﬁll this critical gap in our current
nterventions [13]. Indeed, VIMTs are now considered a develop-
ent priority, as evidenced by their inclusion in the 2013 revision
f the Roadmap.
One class of VIMTs under consideration is the SSM-VIMT, a
umber of which are being developed to induce long-lived anti-
odies that block parasite transmission from infected humans to
osquitoes, thereby breaking the cycle of transmission. Since this
lass of vaccines would confer a delayed beneﬁt to vaccine recipi-
nts (i.e., a community effect), the development pathway for such
 vaccine is complex and has not been deﬁned. However, in 2010,
he FDA indicated that there is no legal bar to considering an SSM-
IMT for licensure and it would be eligible for its review process,
iven that speciﬁc criteria are met. Subsequently, two development
athways have been prioritized for consideration to support the
egulatory approval and eventual implementation of SSM-VIMTs.
he ﬁrst is to seek regulatory approval based on a single, large
RT that attempts to demonstrate vaccine efﬁcacy against inci-
ence of infection/disease, while the second proposes to secure
ccelerated approval, based on analytically and biologically vali-
ated endpoints, enabling a more thorough investigation of true
fﬁcacy in Phase 4 studies. Work is ongoing to fully explore the
erits and limitations of each approach in preparation for consul-
ation with regulatory authorities. The regulatory pathway selected
ill have important implications on a host of associated activities,
ncluding the criticality of identifying an analytically and biologi-
ally validated correlate of transmission-blocking activity. Further,
evelopment and optimal implementation of VIMTs will beneﬁt
rom the effective use of modeling and an ability to reliably detect
ametocyte carriers. The generation of real-time tracking systems
f infection will also be an important tool beyond vaccine develop-
ent to achieve the ultimate goal of eradication.
The ability to communicate the delayed beneﬁt of an SSM-VIMT
o communities and recipients, and the acceptability of such an2 (2014) 5531–5539 5537
intervention is one that needs to be conﬁrmed to ensure that the
vaccine is well received, as coverage will be key to achieving trans-
mission reduction. In addition, economics will be an important
driver, and an SSM-VIMT must be low cost, cost-effective, and ﬁt
within the budget of a country’s malaria elimination program.
Signiﬁcant progress has been made since the malaria com-
munity ﬁrst considered transmission-blocking vaccines; multiple
conferences and consultations have been devoted to the topic, and
the inclusion of transmission reduction as a target in the updated
Roadmap in 2013 provides both the framework and the impetus
for those in the ﬁeld to continue striving toward development of
an SSM-VIMT. While much work still needs be done, measurable
progress has been made in recent years toward identiﬁcation of a
preferred regulatory approval pathway to inform vaccine develop-
ment efforts.
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